News

Life After Hate Launches HateEraser–A Revolutionary Spray Paint Remover to Eliminate Hate-Based Graffiti

HateEraser removes hate-based graffiti in communities and gives first-time offenders a second chance through judge-mandated service NEW YORK, Nov. 16,…

1 week ago

DermRays Black Friday Event Offers Year’s Biggest Savings and Industry Recognition

PLEASANTON, Calif., Nov. 16, 2024 /PRNewswire/ -- This Black Friday, DermRays is excited to announce its most significant sale of…

1 week ago

Addressing Gender Equity and Women’s Empowerment in Underserved Communities

Boston Female Leaders Support Whittier Street Health Center's Vulnerable and Underserved Women and FamiliesBOSTON, MA / ACCESSWIRE / November 16,…

1 week ago

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

1 week ago

Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test

Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic…

1 week ago

Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing

MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced…

1 week ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the…

1 week ago

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”)…

1 week ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform…

1 week ago

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…

1 week ago